What are the diagnostic criteria and management guidelines for hypertensive disorders in pregnancy?

Hypertensive Disorders in Pregnancy: Diagnostic Criteria and Management

Severe-range hypertension (BP >160/110 mm Hg) is a medical emergency requiring treatment within 30-60 minutes with IV labetalol, IV hydralazine, or oral immediate-release nifedipine to prevent maternal stroke and death 1.

Diagnostic Criteria

Blood Pressure Thresholds

Hypertension in pregnancy is diagnosed when:

• Office/clinic BP ≥140/90 mm Hg (consistently measured)
• Home BP ≥135/85 mm Hg 2
• Severe hypertension: BP >160/110 mm Hg 1, 2

Proteinuria Assessment

• Screen with automated dipstick urinalysis
• If positive, quantify with urine protein/creatinine ratio ≥30 mg/mmol (0.3 mg/mg) 2

Management Algorithm

Step 1: Classify Severity

Severe hypertension (>160/110 mm Hg):

• Confirm persistent elevation within 15 minutes
• Treat within 30-60 minutes in monitored setting 1, 2
• First-line agents:
  • IV labetalol
  • IV hydralazine
  • Oral immediate-release nifedipine (if no IV access) 1, 2

Non-severe hypertension (140-159/90-109 mm Hg):

• Initiate treatment for chronic hypertension targeting BP <140/90 mm Hg based on CHAP trial evidence showing reduced preeclampsia with severe features, indicated preterm birth, placental abruption, and fetal/neonatal death (OR 0.82, NNT=14.7) 1
• For gestational hypertension and preeclampsia, target diastolic BP of 85 mm Hg (systolic 110-140 mm Hg) 2

Step 2: Select Antihypertensive Agent

First-line oral agents:

• Methyldopa
• Labetalol
• Nifedipine
• Oxprenolol 2

Second/third-line agents:

• Hydralazine
• Prazosin 2

Critical caveat: Reduce or cease antihypertensives if diastolic BP falls <80 mm Hg 2

Step 3: Determine Care Setting

Preeclampsia - Initial hospital assessment required 2:

• All women must be assessed in hospital at first diagnosis
• May transition to outpatient management if:
  • Condition is stable
  • Patient reliable for BP monitoring and symptom reporting
  • No severe features present

Gestational hypertension:

• Hospital assessment required if severe hypertension (≥160/110 mm Hg) or preeclampsia develops 2

Step 4: Magnesium Sulfate for Seizure Prophylaxis

Indications for MgSO₄ 2:

• Preeclampsia with proteinuria AND severe hypertension
• Preeclampsia with neurological signs/symptoms (severe headache, visual scotomata)

Dosing:

• Loading: 4 g IV or 10 g IM
• Maintenance: 5 g IM every 4 hours OR 1 g/h infusion
• Continue until delivery and ≥24 hours postpartum 2

Step 5: Maternal Monitoring Protocol

For preeclampsia 2:

• BP monitoring (frequency based on severity)
• Repeated proteinuria assessments if not initially present
• Clinical assessment including clonus
• Minimum twice-weekly labs:
  • Hemoglobin
  • Platelet count
  • Liver function tests
  • Renal function tests
  • Uric acid (associated with worse maternal-fetal outcomes)

Step 6: Fetal Surveillance

Initial assessment:

• Confirm fetal well-being with ultrasound 2

Serial monitoring:

• Fetal biometry, amniotic fluid, umbilical artery Doppler
• Every 2 weeks if normal initial assessment
• More frequent monitoring if fetal growth restriction present 2

Step 7: Delivery Timing

Deliver at 37 weeks + 0 days gestation OR earlier if 2:

• Repeated severe hypertension despite 3 antihypertensive classes
• Progressive thrombocytopenia
• Progressively abnormal renal or liver function
• Pulmonary edema
• Severe intractable headache, repeated visual scotomata, or convulsions
• Nonreassuring fetal status

For gestational hypertension without preeclampsia: Delivery at 38-39 weeks appears optimal, though evidence is limited 2

Key Divergence in Guidelines

Critical controversy: The 2025 US guidelines (ACOG/SMFM) recommend treating chronic hypertension to <140/90 mm Hg based on the CHAP trial 1, but do not extend this recommendation to gestational hypertension or preeclampsia due to limited evidence in these populations. In contrast, international guidelines (ISSHP) recommend treating all hypertensive disorders of pregnancy at ≥140/90 mm Hg targeting diastolic BP of 85 mm Hg 2. This reflects ongoing debate about whether chronic hypertension trial data can be extrapolated to other HDPs.

The CHIPS trial showed that tight control (diastolic target 85 mm Hg) versus less-tight control (diastolic target 100 mm Hg) in chronic/gestational hypertension reduced severe maternal hypertension without adverse fetal effects 2, supporting the international approach.

Common Pitfalls

• Delaying treatment of severe hypertension: The 30-60 minute window is critical to prevent intracerebral hemorrhage
• Over-treating and dropping diastolic BP <80 mm Hg: This risks impaired uteroplacental perfusion
• Assuming gestational hypertension is benign: 25% progress to preeclampsia, particularly those presenting <34 weeks 2
• Inadequate postpartum monitoring: HDPs confer long-term cardiovascular risk requiring structured follow-up 1